Geoffrey M. Parker, Chief Financial Officer of Allogene Therapeutics, Inc., filed a Form 4 on October 23, 2026, disclosing a sale of 36,342 shares of common stock on October 21, 2026, along with a forfeiture of 195,000 performance RSU shares.

Key Highlights

  • Mandatory tax-cover sale: Parker disposed of 36,342 shares of Allogene Therapeutics common stock on October 21, 2026, at $1.34 per share, to satisfy tax withholding obligations upon restricted stock unit vesting.
  • Issuer-mandated transaction: According to the filing, the sale "does not represent a discretionary trade by the reporting person" and was required under the issuer's equity incentive plan "sell to cover" election.
  • Performance RSU forfeiture: The filing notes a forfeiture of 195,000 shares subject to performance RSUs granted to Parker on October 10, 2023.
  • Post-transaction ownership: Parker beneficially owned 1,045,877 shares of common stock following the reported transactions, held directly.
  • ESPP acquisitions included: The post-transaction total includes 12,500 shares acquired on March 15, 2026, and 11,924 shares acquired on September 15, 2026, both through the company's employee stock purchase program.
  • Ticker and exchange: Allogene Therapeutics trades on NASDAQ:ALLO.

Parker's Tax-Withholding Sale and Performance RSU Forfeiture at Allogene Therapeutics

According to the Form 4 filed on October 23, 2026, Geoffrey M. Parker, who serves as Chief Financial Officer of Allogene Therapeutics, Inc. (NASDAQ:ALLO), sold 36,342 shares of the company's common stock on October 21, 2026, at a price of $1.34 per share. The filing states this transaction was classified under transaction code "S" and carried a disposition ("D") designation. The filing explicitly describes the sale as one "mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction."

Separately, the filing discloses a forfeiture of 195,000 shares subject to performance restricted stock units that were originally granted to Parker on October 10, 2023. No proceeds are associated with a forfeiture. Following all reported transactions, Parker's direct beneficial ownership stood at 1,045,877 shares of Allogene Therapeutics common stock.

The filing also notes that Parker's total holding incorporates shares acquired through the company's employee stock purchase program: 12,500 shares obtained on March 15, 2026, and 11,924 shares obtained on September 15, 2026. The Form 4 was signed by Earl Douglas as attorney-in-fact on October 23, 2026, with the earliest transaction date listed as October 21, 2026.

What Was Disclosed

Allogene Therapeutics CFO Geoffrey M. Parker disclosed a mandatory tax-withholding sale of 36,342 shares at $1.34, a forfeiture of 195,000 performance RSUs originally granted in 2023, and a resulting direct beneficial ownership of 1,045,877 shares.